Back to all studies
❤️
Phase 1
Cardiology
in-person
Study of Intravenous ZMA001 in Healthy Subjects
Sponsored by National Heart, Lung, and Blood Institute (NHLBI)
Compensation
$500–$2,500
Duration
3 months
Location
Maryland
About this study
Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people. Objective: To test a dru…
Who can participate
- • Adults aged 18–60
- • All genders welcome
- • Diagnosed with or experiencing pulmonary arterial hypertension pah
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.